Insight Molecular Diagnostics Inc. — Director's Dealing 2019

Jul 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2019-07-17

Reporting Person: Last Andrew J. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-07-17	Option to Purchase Common Stock	$2.12	A	45000	Acquired	2029-07-16	Common Stock (45000)	Direct

Footnotes

F1: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.